Follow this innovation
[ via 
] [?]
Inhibition of angiogenesis by antibodies against high molecular weight kininogen domain 5
Temple University
posted on 08/05/2011
The present invention is based upon the discovery that antibodies which bind to HK domain 5 inhibit endothelial cell proliferation, tube formation and neovascularization. This activity confers upon such antibodies the ability to inhibit cytokine-driven angiogenesis in vivo. According to the assays utilized herein, antibodies against HK domain 5 potently inhibit the proliferation of human endothelial cells in vitro in response to a typical endothelial cell growth factor, FGF-2. Such antibodies also inhibit endothelial tube formation, another benchmark of angiogenesis. Furthermore, as shown herein, antibodies against HK domain 5 are effective in an in vivo model of angiogenesis. The antibodies inhibit the growth of new blood vessels in the chorioallantoic membrane of intact living chicken eggs stimulated with FGF-2.
Advantages
• To inhibit undesired angiogenesis in disease states such as diabetic retinopathy, rheumatoid arthritis and atherosclerotic plaques.
File Number: 371RC
| Patent Number(s): | 6994852 |
|---|
This innovation currently is not available for online licensing. Please contact Stephen Nappi at Temple University for more information.
request more info
ProfileFind more innovations
